Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE-Reference-Cited by-同舟云学术

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE

Published:2021-11 Issue:11 Volume:21 Page:785-798
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Mateos Maria-Victoria,Dimopoulos Meletios A.,Cavo Michele,Suzuki Kenshi,Knop Stefan,Doyen Chantal,Lucio Paulo,Nagy Zsolt,Pour Ludek,Grosicki Sebastian,Crepaldi Andre,Liberati Anna Marina,Campbell Philip,Yoon Sung-Soo,Iosava Genadi,Fujisaki Tomoaki,Garg Mamta,Iida Shinsuke,Bladé Joan,Ukropec Jon,Pei Huiling,Van Rampelbergh Rian,Kudva Anupa,Qi Ming,San-Miguel Jesus

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference27 articles.

1. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors;de Weers;J Immunol,2011

2. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79;Lammerts van Bueren;Blood,2014

3. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma;Overdijk;MAbs,2015

4. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via FcΓ receptor-mediated cross-linking;Overdijk;J Immunol,2016

5. Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma;Krejcik;Blood,2016

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quality of life gains in frail and intermediate-fit patients with multiple Myeloma: Findings from the prospective HOVON123 clinical trial;European Journal of Cancer;2024-08

2. Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN;Blood Cancer Journal;2024-07-08

3. Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes;HemaSphere;2024-07

4. Individualized dynamic frailty-tailored therapy (DynaFiT) in elderly patients with newly diagnosed multiple myeloma: a prospective study;Journal of Hematology & Oncology;2024-06-24

5. Personalized Treatment of Multiple Myeloma in Frail Patients;Current Oncology Reports;2024-05-18